TTrialPathMatch Me to Trials
← Back to trials
RecruitingCastration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Eligible age

18+ yrs

Accepts

Men

Locations

31 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Hormone therapy for prostate cancer, also called androgen deprivation therapy (ADT), uses surgery or drugs to lower the levels of male sex hormones in a man's body. This helps slow the growth of prostate cancer. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Giving docetaxel in addition to the usual treatment of hormonal therapy and apalutamide may work better in treating patients with metastatic prostate cancer than the usual treatment alone.

Sponsor: Alliance for Clinical Trials in Oncology

You may qualify if…

  • ✓ Documentation of disease:
  • ✓ \* Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology
  • ✓ Must have had evidence of metastatic disease (American Joint Committee on Cancer \[AJCC\] metastasis \[M\]1 disease) based on conventional CT/MRI and/or bone scan. This will be defined as:
  • ✓ Bone metastases detected by CT, radionuclide technetium-99 (99Tc)- methylene bisphosphonate bone scan, or MRI as defined by PCWG3 criteria; OR
  • ✓ Non-pelvic lymph node metastases (measurable lymph nodes above the aortic bifurcation; lymph nodes are measurable if the short axis diameter is ≥ 15 mm) detected on CT or MRI as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Subjects with regional lymph node metastases only (nodes \[N\]1, below the aortic bifurcation) will not be eligible for the study; OR
  • ✓ Visceral or soft tissue metastases detected on CT or MRI as defined by RECIST version 1.1. Soft tissue/visceral lesions are measurable if the long axis diameter is ≥ 10 mm
  • ✓ Evidence of metastatic disease by PSMA-PET only and not visible by CT, radionuclide bone scan, or MRI will not satisfy eligibility criteria
  • ✓ No metachronous low-volume disease (defined as recurrent metastatic disease after definitive treatment of prostate primary) and with ≤ 4 bone metastasis and no visceral metastasis on conventional imaging by CT, radionuclide 99Tc-biphosphonate bone scan, or MRI)

Where it's recruiting

Arizona

Tucson

California

Dublin · Fremont · Fresno · La Jolla …

Colorado

Aurora · Denver · Edwards · Grand Junction …

Delaware

Dover · Milford

District of Columbia

Washington D.C.

Florida

Gainesville

Georgia

Atlanta · Duluth · Lawrenceville

Hawaii

Honolulu

Idaho

Boise · Coeur d'Alene · Fruitland · Meridian …

Illinois

Bloomington · Canton · Carthage · Centralia …

Iowa

Ames · Boone · Cedar Rapids · Fort Dodge …

Kansas

Hays · Lawrence · Olathe · Overland Park …

Source: ClinicalTrials.gov · NCT06931340 · last updated 2026-11-03

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatmen · TrialPath